PharmacoDesign Purchases Illumina Genotyping Solutions for Pharmacogenomics Research
Illumina to Gain Exclusive, Licensed Access to Biomarkers Discovered Through Disease Studies
Illumina, Inc. announced an agreement of sale with PharmacoDesign (PD) for a BeadStation system and whole-genome genotyping arrays and reagents for ongoing pharmacogenomics studies. PharmacoDesign will genotype various Korean populations with the aim of understanding genetic variation and personalizing treatment for optimal clinical outcomes.
Under the agreement, Illumina will gain access to biomarkers discovered by PD and will be able to incorporate such markers into proprietary SNP panels under a worldwide, royalty-bearing exclusive license.
PD will study diseases that include obesity, cancer and allergy-induced reactions such as atopy. The company works in partnership with large Korean hospitals to prescribe individualized treatments that utilize diet and "functional foods" in addition to traditional pharmacological approaches.
Most read news
Topics
Organizations
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.